



NDA 202155/S-032

SUPPLEMENT APPROVAL

Bristol-Myers Squibb Company
Attention: Isha Majmudar
Global Regulatory Strategist
P.O. Box 5326
Princeton, NJ 08543-5326

Dear Ms. Majmudar:

Please refer to your supplemental new drug application (sNDA) dated and received February 19, 2021, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Eliquis (apixaban) Tablets.

We also refer to our letter dated February 19, 2021, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for novel oral anticoagulants (NOACs). This information pertains to the risk of clinically significant uterine bleeding.

This supplemental new drug application provides for revisions to the labeling for Eliquis, consistent with our February 19, 2021 Safety Labeling Change Notification letter requiring removal of all references to site specific bleeding in Section 6.2 of the approved label; and addition of section 8.3 to describe the risk of clinically significant uterine bleeding in females of reproductive potential.

APPROVAL & LABELING

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling. If the content of labeling in SPL format initially submitted with

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

this CBE-0 labeling supplement is identical to the attached approved labeling, an additional submission of content of labeling in SPL format is not required.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Lori Anne Wachter, RN, BSN, RAC, Acting Regulatory Project Manager for Safety, at 301 796-3975.

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

Sincerely,

{See appended electronic signature page}

Rosanna Setse, MD, PhD.
Deputy Director for Safety
Division of Non-malignant Hematology
Office of Cardiology, Hematology, Endocrinology
and Nephrology
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

ROSANNA W SETSE
04/20/2021 11:28:21 AM